HCA VS NVS Stock Comparison
Performance
HCA10/100
10/100
HCA returned 4.32% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
NVS100/100
100/100
NVS returned 11.56% in the last 12 months. Based on SPY's performance of -13.77%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
HCA75/100
75/100
22 analysts offer 12-month price targets for HCA. Together, they have an average target of 265.95, the most optimistic target put HCA at 315 within 12-months and the most pessimistic has HCA at 200.
NVS67/100
67/100
3 analysts offer 12-month price targets for NVS. Together, they have an average target of 0, the most optimistic target put NVS at 0 within 12-months and the most pessimistic has NVS at 0.
Technicals
HCA50/100
50/100
HCA receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.
NVS10/100
10/100
NVS receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
Earnings
HCA10/100
10/100
HCA has missed earnings 6 times in the last 20 quarters.
NVS39/100
39/100
NVS has missed earnings 5 times in the last 20 quarters.
Profit
HCA78/100
78/100
Out of the last 20 quarters, HCA has had 20 profitable quarters and has increased their profits year over year on 10 of them.
NVS73/100
73/100
Out of the last 20 quarters, NVS has had 20 profitable quarters and has increased their profits year over year on 8 of them.
Volatility
HCA49/100
49/100
HCA has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.
NVS44/100
44/100
NVS has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
Dividend
HCA23/100
23/100
HCA's most recent dividend was $0.35 per share, based on a share price of $237.58. It was a payout ratio of 11.37% compared to their total earnings.
NVS
"Dividend" not found for NVS
All score calculations are broken down here to help you make more informed investing decisions
HCA Healthcare, Inc. Summary
New York Stock Exchange / HCA
Healthcare
Medical - Care Facilities
HCA Healthcare, Inc., through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. It also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, the company operates psychiatric hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. As of December 31, 2021, it operated 182 hospitals, including 175 general and acute care hospitals, five psychiatric hospitals, and two rehabilitation hospitals; 125 freestanding surgery centers; and 21 freestanding endoscopy centers in 20 states and England. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
Novartis AG Summary
New York Stock Exchange / NVS
Healthcare
Drug Manufacturers - General
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare HCA to other companies in the same or a similar industry.